Grifols, S.A. has signed an agreement with MassBiologics, or MBL, of the University of Massachusetts Medical School that gives Grifols exclusive rights to market and distribute MBL's tetanus and diphtheria toxoids adsorbed, or Td, vaccine in the US with the exception of Massachusetts, where MBL will continue distributing the vaccine.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
9.078 EUR | -1.43% | -5.59% | -40.99% |
07-15 | European Equities Traded in the US as American Depositary Receipts Start Week Lower in Monday Trading | MT |
07-14 | Moody's Removes Rating of Spanish Pharmaceutical Grifols | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-40.99% | 6.32B | |
+7.40% | 101B | |
+7.76% | 42.18B | |
-14.37% | 32.26B | |
+80.10% | 29.79B | |
-12.27% | 16.06B | |
+2.33% | 14.45B | |
-8.56% | 12.01B | |
+182.74% | 10.71B | |
+3.75% | 8.89B |
- Stock Market
- Equities
- GRF Stock
- News Grifols, S.A.
- Grifols, S.A. Signs Marketing and Distribution Agreement with MassBiologics